C16 Biosciences vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;
About
C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.